3 | Έρπης ζωστήρας

30.

ΕΟΔΥ, Ενημέρωση διαπιστευμένων συντακτών για το Εθνικό Σχέδιο εμβολιαστικής κάλυψης κατά της COVID-19, από την Πρόεδρο της Εθνικής Επιτροπής Εμβολιασμών Μαρία Θεοδωρίδου και τον Γ.Γ. Πρωτοβάθμιας Φροντίδας Υγείας Μάριο Θεμιστοκλέους, https://eody.gov.gr/enimerosi-20210222/?print=print, ημερομηνία πρόσβασης: 1/3/2021

29.

Φύλλο Οδηγιών Χρήσης Εμβολίου Έρπητα ζωστήρα (από ζώντες ιούς), Αύγουστος 2020

28.

Εγκύκλιος Υπουργείου Υγείας, Εθνικό Πρόγραµµα Εμβολιασμών Ενηλίκων 2020-2021, Αριθ. Πρωτ. Δ1α/Γ.Π.οικ.74363, 19/11/2020

27.

Yawn BP, Saddier P, Wollan PC, et al. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc. 2007;82(11):1341–1349.

26.

Johnson RW. Consequences and management of pain in herpes zoster. J Infect Dis. 2002;186(suppl 1):S83–S90.

25.

Katz J, Melzack R. Measurement of pain. Surg Clin North Am. 1999;79(2):231–252

24.

Schmader KE. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain. 2002;18(6):350–354.

23.

Harpaz R et al. Prevention of Herpes Zoster Recommendations of the Advisory Committee on Immunization Practices (ACIP), MMWR. 2008;RR-5):1–30.

22.

Guignard AP, Greenberg M, Lu C, Rosillon D, Vannappagari V. Risk of herpes zoster among diabetics: a matched cohort study in a US insurance claim database before introduction of vaccination, 1997-2006. Infection. 2014;42:729-35.

21.

Katz J, Cooper EM, Walther RR, et al. Acute pain in herpes zoster and its impact on health-related quality of life. Clin Infect Dis. 2004;39(3):342–348

20.

Johnson R, McElhaney J, Pedalino B et al, Prevention of herpes zoster and its painful and debilitating complications. Int J Infect Dis (Supplement) 2007; 11 S2:S43-S48.

19.

Galil K et al. The sequelae of Herpes Zoster. Arch Intern Med 1997; 157: 1209-1213.

18.

Oxman MN. Clinical manifestations of herpes zoster. In: Arvin AM, Gershon AA, eds. Varicella-Zoster Virus. Virology and clinical management. Cambridge: Cambridge University Press; 2000. p. 246-75.

17.

Pavan-Langston D.Ophthalmic zoster. In: Arvin AM, Gershon AA eds. Varicella-Zoster virus – Virology and clinical management. Cambridge: Cambridge University Press; 2000;N/A: p276-98.

16.

Cunningham AL, Breuer J, Dwyer DE et al. The prevention and management of herpes zoster. Med J Aust 2008;188: 171-6.

15.

Drolet M. Employment related productivity loss associated with herpes zoster and postherpetic neuralgia: A 6-month prospective study. Vaccine 2012;30:2047-50.

14.

Drolet M et al. The impact of herpes zoster and postherpetic neuralgia CMAJ 2010;N/A: DOI:10.1503/cmaj.091711.

13.

Weinke T et al. Impact of herpes zoster and post-herpetic neuralgia on patients’ quality of life: a patient-reported outcomes survey J Public Health 2010;18(4): 367-374.

12.

Johnson RW. Zoster associated pain: what is known, who is at risk and how can it be managed? Herpes 2007;14 (s2): 30A-34A.

11.

Helgason S, Petursson G, Gudmundsson S et al. Prevalence of postherpetic neuralgia after a single episode of herpes zoster: prospective study with long term follow up. Br Med J 2000; 321: 1-4.

10.

Johnson RW et al. The impact of herpes zoster and post-herpetic neuralgia on quality-of-life. BMC Med 2010;8:1-13.

9.

Hope-Simpson RE. Postherpetic neuralgia. JR Coll Gen Practice 1975;25: 571-5.

8.

Forbes HJ, Bhaskaran K, Thomas SL, Smeeth L, Clayton T, Langan Sm. Quantification of risk factors for herpes zoster: population based case-control study. BMJ 2014;348:g2911.

7.

Miller E, Marshall R, Vurdien J. Epidemiology, outcome and xontrol of varicella-zosterin- fection Rev Med Micro 1993;4: 222-30.

6.

Browsher D. The lifetime occurrence of Herpes Zoster and prevalence of post-herpetic neuralgia: A retrospective survey in an elderly population. Eur J Pain 1999;3: 335-42.

5.

Burke BL: Steele RW; Beard OW; Wood JS; Cain TD; Marmer DJ. Immune Responses to Varicalla-Zoster in the Aged. Arch Intern Med 1982; 42:291-293.

4.

Johnson RW. Herpes Zoster and Postherpetic Neuralgia: a review of the effects of vaccination Aging Clin Exp Res 2009;21: 236-243.

3.

Oxman MN. Zoster Vaccine: Current Status and Future Prospects Clinical Infectious Diseases 2010;52(2): 197-213.

2.

Arvin A. Aging, immunity, and the varicella zoster virus. N. Engl J Med 2005;352:2266-67.

1.

Johnson RW, Wasner G, Saddier P et al. Postherpetic Neuralgia: epidemiology, pathology and management. Expert Rev Neurothen 2007;7: 1581-95.

3

Author Katerina Molyva